News

The study included three dose levels of Progenta as well as placebo and positive control arms. The positive control was Abbott’s Lucrin, an approved gonadotropin releasing agonist (GnRHa),

Vicuron’s investigational agent, dalbavancin, is a novel once-weekly antibiotic for the treatment of complicated skin and soft tissue infections (cSSTIs) including the most difficult to treat strain of

The company is currently testing alagebrium in patients with systolic hypertension, heart failure and erectile dysfunction. Patients already enrolled in the clinical trials are continuing treatment. In December

The verdict came at the close of the first phase, the damages phase, of this bifurcated (two-phase) trial. This ruling completes the litigation associated with the two cases.

Orchid’s responsibilities will include development of active pharmaceutical ingredients, development of final formulations, and manufacture of finished products for exclusive sale by Alpharma in the US and Europe.

Genzyme’s experimental therapy, using Ad2/HIF-1 alpha, an engineered form of the HIF-1 alpha gene, is designed to promote the growth of new blood vessels and improve circulation in

Data from the pilot study, which evaluated the safety and efficacy of Hyalgan (sodium hyaluronate) versus saline in the treatment of osteoarthritis (OA) of the ankle, suggested that

DOV 102,677 is believed to be a potent inhibitor of serotonin, norepinephrine and dopamine reuptake, with preferential action on the dopamine transporter protein. This clinical trial is a

The phase II clinical trial is an open-label study to evaluate the efficacy, safety and tolerability of HGS-ETR1 (mapatumumab) in patients with relapsed or refractory colorectal cancer. The